Triple Drug Therapy (India)

To determine the frequency, type and severity of adverse events following triple-drug therapy (IVM+DEC+ALB, IDA) compared to the standard two-drug treatment (DEC+ALB, DA) in infected and uninfected individuals in a community.

To compare the efficacy of IDA vs. DA administered in communities for clearance of Mf and filarial antigenemia (Ag) in cohort and effectiveness (prevalence) in community settings. To assess the presence and intensity of filarial infection on the frequency and severity of adverse events. To compare community acceptance of MDA with IDA vs. DA.

Sites

WHO Region: SEARO

Publications

The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study

Weil GJ, Bogus J, Christian M, Dubray C, Djuardi Y, et al.
2019, Issue no. 6, pages (6): e1002839

Frequency and Clinical Significance of Localized Adverse Events following Mass Drug Administration for Lymphatic Filariasis in an Endemic Area in South India

Vijesh Sreedhar Kuttiatt, Roopali K. Somani, Subramanian Swaminathan, Kaliannagounder Krishnamoorthy, Gary J. Weil, Jambulingam Purushothaman
2020, Issue no. 1, pages 96-99

Notes

This study is associated with NCT02899936.

Email primary contact

Please log in or register